Celgene Co. (CELG) Upgraded to Strong-Buy at Vetr Inc.

Celgene Co. (CELG) Upgraded to Strong-Buy at Vetr Inc.


The firm presently has a $133.83 price objective on the biopharmaceutical company's stock. Vetr 's price target points to a potential upside of 10.90% from the company's current price.



from Biotech News